300 related articles for article (PubMed ID: 27593928)
1. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.
Tsai CT; So CW
Oncogene; 2017 Mar; 36(13):1753-1759. PubMed ID: 27593928
[TBL] [Abstract][Full Text] [Related]
2. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy.
Boila LD; Sengupta A
Exp Hematol; 2020 Dec; 92():19-31. PubMed ID: 32950598
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic small molecule modulators of histone and DNA methylation.
Hauser AT; Robaa D; Jung M
Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
[TBL] [Abstract][Full Text] [Related]
4. Targeting histone lysine methylation in cancer.
McGrath J; Trojer P
Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
[TBL] [Abstract][Full Text] [Related]
5. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
6. Histone modification therapy of cancer.
Biancotto C; Frigè G; Minucci S
Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
[TBL] [Abstract][Full Text] [Related]
7. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic strategies for MLL-rearranged leukemias.
Wong NM; So CWE
Biochim Biophys Acta Gene Regul Mech; 2020 Sep; 1863(9):194584. PubMed ID: 32534041
[TBL] [Abstract][Full Text] [Related]
9. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
12. Targeting the histone orthography of cancer: drugs for writers, erasers and readers.
Simó-Riudalbas L; Esteller M
Br J Pharmacol; 2015 Jun; 172(11):2716-32. PubMed ID: 25039449
[TBL] [Abstract][Full Text] [Related]
13. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
14. Targeting Histone Methylation in Cancer.
McCabe MT; Mohammad HP; Barbash O; Kruger RG
Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430
[TBL] [Abstract][Full Text] [Related]
15. Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases.
Wang Z; Patel DJ
Q Rev Biophys; 2013 Nov; 46(4):349-73. PubMed ID: 23991894
[TBL] [Abstract][Full Text] [Related]
16. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
Murray-Stewart T; Woster PM; Casero RA
Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
[TBL] [Abstract][Full Text] [Related]
17. Promises and challenges of anticancer drugs that target the epigenome.
Verbrugge I; Johnstone RW; Bots M
Epigenomics; 2011 Oct; 3(5):547-65. PubMed ID: 22126246
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.
Reikvam H; Hoang TT; Bruserud Ø
Expert Rev Hematol; 2015 Jun; 8(3):315-27. PubMed ID: 25901742
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease.
Bhat KP; Ümit Kaniskan H; Jin J; Gozani O
Nat Rev Drug Discov; 2021 Apr; 20(4):265-286. PubMed ID: 33469207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]